Enveric Biosciences, Inc. (ENVB) stock
ENVBNasdaqPharmaceutical PreparationsFiscal year ends December 31
$1.42+0.01 (+0.71%)
Close on Nov 18, 2026Market cap $6.36MP/E –Yield –
Enveric Biosciences free cash flow
Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.
Enveric Biosciences's free cash flow for the twelve months ending Dec 31, 2023 was -$14.10M. For fiscal 2023 it was -$14.10M.
Annual free cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2023 | Dec 31, 2023 | -$14.10M | – |
| FY2022 | Dec 31, 2022 | -$17.73M | – |
| FY2021 | Dec 31, 2021 | -$11.65M | – |
Quarterly free cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q4 FY2023 | Dec 31, 2023 | -$1.75M | – |
| Q3 FY2023 | Sep 30, 2023 | -$2.74M | – |
| Q2 FY2023 | Jun 30, 2023 | -$4.47M | – |
| Q1 FY2023 | Mar 31, 2023 | -$5.14M | – |
| Q4 FY2022 | Dec 31, 2022 | -$3.47M | – |
| Q3 FY2022 | Sep 30, 2022 | -$4.57M | – |
| Q2 FY2022 | Jun 30, 2022 | -$4.64M | – |
| Q1 FY2022 | Mar 31, 2022 | -$5.05M | – |
See a number that looks wrong?